目的 研究肾炎安胶囊联合来氟米特片治疗肾病综合征的临床疗效。方法 选取2017年3月-2019年3月四川省第二中医医院收治的60例肾病综合征患者为研究对象，将所有患者随机分为对照组和治疗组，每组各30例。对照组患者口服来氟米特片，2片/次，1次/d；治疗组患者在对照组基础上口服肾炎安胶囊，2粒/次，3次/d。两组患者持续治疗2个月。观察两组的临床疗效，比较两组的肾功能指标、血清炎性因子水平。结果 治疗后，对照组和治疗组的总有效率分别为83.33%、93.33%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者血肌酐（Scr）和24 h尿蛋白（24 h Upro）水平均显著降低，血浆白蛋白（Alb）水平显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组Scr、Alb和24 h Upro水平明显优于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组患者CRP、TNF-α、IL-6水平明显低于对照组，两组比较差异有统计学意义（P<0.05）。结论 肾炎安胶囊联合来氟米特片治疗肾病综合征具有较好的治疗效果，可改善肾功能指标，降低血清炎性因子水平，具有一定的临床推广应用价值。

Objective To study the efficacy of Shenyanan Capsules combined with Leflunomide Tablets in treatment of nephrotic syndrome. Methods Patients (60 cases) with nephrotic syndrome in Sichuan 2nd Hospital of Traditional Chinese Medicine from March 2017 to March 2019 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were po administered with Leflunomide Tablets, 2 tablets/time, once daily. Patients in the treatment group were po administered with Shenyanan Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacies were evaluated, and renal function indexes, and serum levels of inflammatory factors in the groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.33% and 93.33%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of Scr and 24 h Upro in two groups were significantly decreased, but the levels of Alb in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the renal function indexes levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of CRP, TNF-α, and IL-6 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serum levels of inflammatory factors in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Shenyanan Capsules combined with Leflunomide Tablets has clinical curative effect in treatment of nephrotic syndrome, can improve renal function indexes, and reduce the level of serum inflammatory factors, which has a certain clinical application value.

R983